TAK vs. SNY, GSK, ARGX, BNTX, TEVA, BGNE, SMMT, MRNA, GMAB, and VTRS
Should you be buying Takeda Pharmaceutical stock or one of its competitors? The main competitors of Takeda Pharmaceutical include Sanofi (SNY), GSK (GSK), argenx (ARGX), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Summit Therapeutics (SMMT), Moderna (MRNA), Genmab A/S (GMAB), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.
Takeda Pharmaceutical vs.
Sanofi (NASDAQ:SNY) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, community ranking, earnings, valuation and risk.
Sanofi has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.
Sanofi pays an annual dividend of $1.48 per share and has a dividend yield of 2.7%. Takeda Pharmaceutical pays an annual dividend of $0.53 per share and has a dividend yield of 3.9%. Sanofi pays out 75.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Takeda Pharmaceutical pays out 91.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Sanofi currently has a consensus price target of $60.00, suggesting a potential upside of 10.80%. Given Sanofi's stronger consensus rating and higher possible upside, equities research analysts plainly believe Sanofi is more favorable than Takeda Pharmaceutical.
Sanofi has a net margin of 9.96% compared to Takeda Pharmaceutical's net margin of 6.49%. Sanofi's return on equity of 27.45% beat Takeda Pharmaceutical's return on equity.
14.0% of Sanofi shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Takeda Pharmaceutical received 51 more outperform votes than Sanofi when rated by MarketBeat users. However, 60.49% of users gave Sanofi an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.
In the previous week, Sanofi had 33 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 46 mentions for Sanofi and 13 mentions for Takeda Pharmaceutical. Sanofi's average media sentiment score of 0.88 beat Takeda Pharmaceutical's score of 0.56 indicating that Sanofi is being referred to more favorably in the media.
Sanofi has higher revenue and earnings than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.
Summary
Sanofi beats Takeda Pharmaceutical on 19 of the 21 factors compared between the two stocks.
Get Takeda Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Takeda Pharmaceutical Competitors List
Related Companies and Tools
This page (NYSE:TAK) was last updated on 1/30/2025 by MarketBeat.com Staff
